Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 4:5:1263422.
doi: 10.3389/frph.2023.1263422. eCollection 2023.

Adherence to daily, oral TDF/FTC PrEP during periconception among HIV-exposed South African women

Affiliations

Adherence to daily, oral TDF/FTC PrEP during periconception among HIV-exposed South African women

Kathleen E Hurwitz et al. Front Reprod Health. .

Abstract

Background: Daily, oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as pre-exposure prophylaxis (PrEP) reduces HIV acquisition for African women. Adherence is key to efficacy and patterns of adherence can be highly variable in real-world settings. Using group-based trajectory modeling (GBTM), we sought to identify distinct patterns of periconception PrEP adherence and evaluate potential baseline predictors of such adherence trajectories.

Methods: We conducted a single-arm longitudinal study for women aged 18-35 years living in Durban, South Africa with personal or partner plans for pregnancy with a partner with HIV or of unknown serostatus. Participants were offered safer conception counseling, including daily oral PrEP; women who initiated PrEP were given a bottle with an electronic pillcap that recorded when device opens. Weekly adherence to daily PrEP was modeled using GBTM with a censored normal outcome distribution as a function of weeks since PrEP initiation. The number and functional form of the adherence trajectory groups were primarily selected based on Bayesian information criteria (BIC) and confirmed by mean estimated probabilities of group membership. A multivariable version of the selected model assessed baseline predictors of membership in adherence trajectory groups.

Results: Overall mean (95% CI) adherence to PrEP was 63% (60%, 67%). We identified four groups of women with distinct patterns of adherence: (1) high (i.e., ≥6 doses per week) steady adherence throughout follow-up (22% of PrEP initiators); (2) moderate (i.e., 4-5 doses per week), but steady adherence (31%); (3) initially high, but consistently declining adherence (21%); and (4) initially moderate adherence, followed by a rapid decline and subsequent rebound (26%). In multivariable-adjusted analyses, older age was associated with membership in the high, steady adherence group as compared to the group identified with an adherence trajectory of initially high, then decline, and finally a rebound.

Conclusions: GBTM is useful for exploring potential heterogeneity in longitudinal patterns of medication adherence. Although a large proportion of women in this study achieved high levels of adherence by electronic pillcap initially, far fewer women maintained these levels consistently. Knowledge of different adherence trajectories could be used to develop targeted strategies for optimizing HIV prevention during periconception.

Keywords: HIV prevention; adherence; group-based trajectory modeling (GBTM); oral pre-exposure prophylaxis (PrEP); periconception; women.

PubMed Disclaimer

Conflict of interest statement

LM received operational support from Gilead Sciences for this project. JH has been a consultant for Merck and owns stock in Natera. JB is an employee of Gilead Sciences, outside of the present work. KEH, KRH and KB are employed by and own equity in Target RWE, which has received fees from Amgen, Baxter International, Gilead Sciences, Janssen Research & Development (Janssen R&D), and Merck outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Summary of enrollment, eligibility, and retention of cohort included in trajectory analysis.
Figure 2
Figure 2
Observed (solid lines) and predicted (dashed lines) weekly adherence to PrEP over 39 months of follow-up assuming 2, 3, 4, and 5 trajectory groups and third-order polynomial terms for time since PrEP initiation.
Figure 3
Figure 3
Observed (solid lines) and predicted (dashed lines) weekly adherence to PrEP over 39 months of follow-up assuming four trajectory groups and up to second-order polynomial terms for time since PrEP initiation.

References

    1. Human Sciences Research Council, S.A. South African National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017. Human Sciences Research Council, S.A; 2018).
    1. Matthews LT, Baeten JM, Celum C, Bangsberg DR. Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation. AIDS Lond Engl. (2010) 24(13):1975–82. 10.1097/QAD.0b013e32833bedeb - DOI - PMC - PubMed
    1. Heffron R, Pintye J, Matthews LT, Weber S, Mugo N. PrEP as peri-conception HIV prevention for women and men. Curr HIV/AIDS Rep. (2016) 13(3):131–9. 10.1007/s11904-016-0312-1 - DOI - PMC - PubMed
    1. Murnane PM, Celum C, Mugo N, Campbell JD, Donnell D, Bukusi E, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS. (2013) 27(13):2155–60. 10.1097/QAD.0b013e3283629037 - DOI - PMC - PubMed
    1. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. (2012) 367(5):423–34. 10.1056/NEJMoa1110711 - DOI - PubMed